SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations
Sign Up to like & getrecommendations! Published in 2020 at "iScience"
DOI: 10.1016/j.isci.2020.101832
Abstract: Summary Tepotinib is an oral MET inhibitor approved for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations. Examining treatment-naive or tepotinib-resistant cells with MET amplification or METex14 skipping mutations identifies… read more here.
Keywords: response tepotinib; influences therapeutic; shp2 inhibition; inhibition influences ... See more keywords
Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Research"
DOI: 10.1158/0008-5472.can-20-1756
Abstract: These findings demonstrate that allosteric SHP2 inhibitors have multivariate and context-dependent effects in glioblastoma that may make them useful components of some combination therapies, but not others. Oncogenic protein tyrosine phosphatases have long been viewed… read more here.
Keywords: glioblastoma; response; shp2 inhibitors; shp2 ... See more keywords
Abstract 1943: SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-1943
Abstract: Direct targeting of oncogenic mutations in the RAS pathway, such as mutant EGFR, BRAFV600E, and most recently KRASG12C, has emerged as a beneficial therapeutic strategy for patients with cancers bearing these mutations. Mutant-selective inhibitors offer… read more here.
Keywords: shp2 inhibition; selective inhibitors; oncogenic mutations; mutations ras ... See more keywords
Abstract A44: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras18-a44
Abstract: FGFR1 was recently shown to be activated as part of a compensatory response to prolonged treatment with MEK inhibitor trametinib in several KRAS-mutant lung and pancreatic cancer cell lines. We hypothesize that other receptor tyrosine… read more here.
Keywords: mek inhibitors; cancer; kras mutant; shp2 inhibition ... See more keywords
SHP2 inhibition enhances Yes-associated protein–mediated liver regeneration in murine partial hepatectomy models
Sign Up to like & getrecommendations! Published in 2022 at "JCI Insight"
DOI: 10.1172/jci.insight.159930
Abstract: Disrupted liver regeneration following hepatectomy represents an “undruggable” clinical challenge associated with poor patient outcomes. Yes-associated protein (YAP), a transcriptional coactivator that is repressed by the Hippo pathway, is instrumental in liver regeneration. We have… read more here.
Keywords: regeneration; nsc 87877; liver regeneration; shp2 inhibition ... See more keywords